National Medicare Analysis Opened For Watchman Device
This article was originally published in The Gray Sheet
CMS will consider a national policy for the left atrial appendage closure device in response to a request from Boston Scientific.
You may also be interested in...
In an exclusive podcast interview with "The Gray Sheet," Ken Stein, Boston Scientific's chief medical officer for cardiac rhythm management, says the company is well positioned to expand adoption of its novel Watchman left-atrial appendage closure device after a challenging regulatory process. He says CMS' recent denial of a new-technology add-on payment is actually good news for the device and the company is looking forward to that agency establishing a national coverage policy.
The positive hospital inpatient reimbursement decision for recently launched Medtronic and CR Bard peripheral artery devices follows prior positive policy rulings in the outpatient setting. Meanwhile, CMS rejected Boston Scientific's new-technology add-on application for the Watchman stroke device, but the agency did establish a pricier payment category for the new procedure.
The American College of Cardiology, Heart Rhythm Society, and Society for Cardiovascular Angiography and Interventions released an overview of left atrial appendage occlusion devices, specifically Boston Scientific's Watchman and SentreHEART's Lariat.